Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

About this update from Veracyte, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4609,"height":986,"url":"https://media.zenfs.com/en/business-wire.com/c73b8438a61bd8a90c8501f6f4c2a192"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AWiyeKy0uCYDRpKGfLn2JQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwNTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c73b8438a61bd8a90c8501f6f4c2a192","width":960,"height":205},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/6G7moIMOxnR_faIyEn01IQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c73b8438a61bd8a90c8501f6f4c2a192","width":1200,"height":257}},"lazy":false},{"type":"text","content":"Grew full-year revenue to between $515 million and $517 million, an increase of 16%","length":83,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., January 11, 2026--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025.","length":251,"tagName":"p"},{"type":"text","content":"Preliminary Unaudited Financial Results","length":39,"tagName":"p"},{"type":"text","content":"For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report:","length":115,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue of between $138 million and $140 million, an increase of between 16% and 18%","length":90,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Testing revenue of between $134 million and $136 million, an increase of between 19% and 21%","length":92,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Testing volume of approximately 45,500, an increase of 16%","length":58,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":240,"olType":false},{"type":"text","content":"For the full year ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report:","length":110,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue of between $515 million and $517 million, an increase of approximately 16%","length":88,"tagName":"p","attribs":{}}]},{"val":[{"...

More updates from Veracyte, Inc.